immunotherapy

Scancell expands cancer research deal with Karolinska Institute

Research will develop drugs in a wider range of cancers

Scancell expands cancer research deal with Karolinska Institute

https://pharmaphorum.com/news/scancell-expands-cancer-research-deal-karolinska/

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

Challenges facing Immuno-Oncology industry

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

https://pharmaphorum.com/partner-content/immuno-oncology-challenges-include-identifying-patients-before-therapy-limited-responses-and-biomarker-research/

EU regulators reject new use for Opdivo, as Keytruda edges ahead

Keytruda begins to win battle of the immunotherapies

EU regulators reject new use for Opdivo, as Keytruda edges ahead

https://pharmaphorum.com/news/eu-regulators-reject-new-use-for-opdivo-as-keytruda-edges-ahead/

NeoAg Summit 2018

one-stop shop of information for advancing your NeoAg

NeoAg Summit 2018

https://pharmaphorum.com/events/neoag-summit-2018/

Lung cancer drug Keytruda to become routinely available on NHS

NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment

Lung cancer drug Keytruda to become routinely available on NHS

https://pharmaphorum.com/news/lung-cancer-drug-keytruda-nhs/

9th World Bispecific Summit

Your Annual Bispecifics Meeting

9th World Bispecific Summit

https://pharmaphorum.com/events/9th-world-bispecific-summit/

Rational Combinations 360

Addressing key aspects across all facets of combination

Rational Combinations 360

https://pharmaphorum.com/events/rational-combinations-360-2/

Immuno-Oncology

Immuno-Oncology Main Conference: 26 – 27 September 2018 Pre-Conference Workshops: 25 September 2018 Copthorne Tara Hotel, London, UK

Immuno-Oncology

https://pharmaphorum.com/events/immuno-oncology/

Merck shows canny cancer strategy in $5.76bn Eisai milestones deal

Firms will co-develop Lenvima and Keytruda combinations

Merck shows canny cancer strategy in $5.76bn Eisai milestones deal

https://pharmaphorum.com/news/merck-co-eisai-forge-5-76bn-cancer-drug-deal/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

immunotherapy